Revvity vs Becton Dickinson and: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Revvity Inc. (RVTY)

Q3 202617 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

August 202617 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

Latest17 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

Becton Dickinson and Company (BDX)

Q3 202630 Jul – 6 Oct 2026

▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.
This is the core financial result that directly moved BDX shares and confirms business momentum.
GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.
It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.
Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.
It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.
$19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.
It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

September 202630 Jul – 6 Oct 2026

▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.
This is the core financial result that directly moved BDX shares and confirms business momentum.
GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.
It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.
Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.
It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.
$19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.
It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Latest30 Jul – 6 Oct 2026

▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.
This is the core financial result that directly moved BDX shares and confirms business momentum.
GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.
It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.
Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.
It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.
$19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.
It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.